Related references
Note: Only part of the references are listed.Management of Waldenstrom macroglobulinemia in 2020
Jorge J. Castillo et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy et al.
BLOOD ADVANCES (2020)
Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
John Apostolidis et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial
Melody R. Becnel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse
Anita Kumar et al.
BLOOD CANCER JOURNAL (2019)
Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Kastritis et al.
ANNALS OF ONCOLOGY (2018)
Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
Christina Kalpadakis et al.
BLOOD (2018)
CD3+/CD8+T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients
Yunfei Shi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
Nathan M. Denlinger et al.
CANCER MANAGEMENT AND RESEARCH (2018)
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
Kensei Tobinai et al.
ADVANCES IN THERAPY (2017)
The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy
Sara Alonso-Alvarez et al.
LEUKEMIA & LYMPHOMA (2017)
A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
M.L. Palomba et al.
HEMATOLOGICAL ONCOLOGY (2017)
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)
M. Herold et al.
HEMATOLOGICAL ONCOLOGY (2017)
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
Emanuele Zucca et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
David W. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Roles for Innate Immunity in Combination Immunotherapies
Kelly D. Moynihan et al.
CANCER RESEARCH (2017)
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Waldenstrom Macroglobulinemia: Review of Pathogenesis and Management
Seongseok Yun et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy et al.
BLOOD (2017)
Postibrutinib outcomes in patients with mantle cell lymphoma
Peter Martin et al.
BLOOD (2016)
Optimizing therapy for nodal marginal zone lymphoma
Catherine Thieblemont et al.
BLOOD (2016)
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
C. Y. Cheah et al.
ANNALS OF ONCOLOGY (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Roger G. Owen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Survival of Patients With Marginal Zone Lymphoma Analysis of the Surveillance, Epidemiology, and End Results Database
Adam J. Olszewski et al.
CANCER (2013)
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
E. Matutes et al.
LEUKEMIA (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma
C Copie-Bergman et al.
GUT (2003)
Share Paper
